LSDEarly Phase 1MESA-XNCT07061886
Drug Effects on Mood and Behavior - Expectancy
A Early Phase 1 study testing LSD in people with LSD, run by University of Chicago at 1 site in United States.
Trial summary
This study will examine the effects of a single low dose of the 5HT2A agonist LSD (Lysergic Acid Diethylamide) (13 µg) or placebo in individuals who are or are not explicitly told what drug they will receive. Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- LSD
- What is being tested?
- LSD
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 42 participants
- Where
- 1 siteUnited States
- Study dates
- 26 Jun 2025to 5 Jun 2026
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- English Fluency
- High school education or higher
- BMI between 19-30 kg/m2
Who cannot join
- Individuals with a medical condition contraindicating study participation as determined by the study physician (e.g., liver disease, abnormal EKG, liver or cardiovascular disease)
- High blood pressure (>140/90)
- Current suicidal ideation or suicide attempt in past 12 months
- Past year severe substance use disorder
- Personal or first-degree relative with history of psychosis
- Currently taking any psychiatric medication (for conventional antidepressants must be off for ≥ 2 weeks)
Show all 10Show fewer
- Active panic disorder
- Severe obsessive-compulsive disorder
- Severe post-traumatic stress disorder
- Women who are pregnant or planning to become pregnant
Trial locations and contacts
1 site in 1 country.
About this study
This study will examine the effects of a single low dose of the 5HT2A agonist LSD (Lysergic Acid Diethylamide) (13 µg) or placebo in individuals who are or are not explicitly told what drug they will receive. Although it is known that expectancies strongly influence subjective responses to most drugs, no studies have examined expectancies on response to a very low dose of LSD. This is especially important in the context of 'microdosing' of drugs. People who practice microdosing typically do so with strong expectations of positive effects, making it difficult to determine whether there is a pharmacological effect. To minimize expectancies in the laboratory, participants are usually not told exactly what drug they will receive (i.e., double-blind), but given a range of possibilities. In the present study, the study team will test half the subjects under single-blind conditions, where the participants (but not the research assistant) will know exactly what they are receiving. Other subjects will receive the usual instructions. Healthy volunteers will receive either a marginally detectable dose of LSD (13 micrograms) or placebo, under conditions where they i) know for sure what drug they are receiving or ii) where the identity of the drug is uncertain. Four groups of subjects (N=12 each) will attend single 4-hour laboratory session. The study team will examine subjective and behavioral responses to the drug in each of four conditions (Known-Drug; Known-Placebo; Uncertain-Drug; Uncertain-Placebo).
Read the detailed description
Expectancies are known to influence responses to psychoactive drugs. The study team and others have shown previously, using a balanced placebo design, that expectancies influence responses to alcohol, nicotine, caffeine, stimulant drugs, and cannabinoids. In these studies subjects are randomly assigned to one of four conditions: Expect the drug and get the drug; Expect the drug and get placebo; Expect placebo and get the drug; Expect placebo and get placebo. This allows researchers to separate pharmacological effects from expectancy effects.
Recently there has been much discussion about the role of expectancies specifically in responses to psychedelic drugs. Expectancies are especially important in the use of very low doses, referred to as 'microdoses'. These doses are typically at or below the threshold of detectability, but users take them with strong prior beliefs that the drugs improve mood and cognition. The beneficial effects have been difficult to demonstrate under laboratory conditions, perhaps because in the laboratory the drugs are administered without the explicit expectation of benefits, and the administration of the drugs is to some extent blinded. The present study is designed to separate the pharmacological effects of a low dose of LSD from effects that are influenced by expectancies.
- Conditions
- LSD
- Being tested
- LSD, Placebo
- Keywords
- Healthy Adults
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LSDDrug
Also called Lysergic acid diethylamide
The serotonin 2A receptor agonist LSD
PlaceboDrug
Distilled water (0.26 mL)
| Study group | Role | What they receive |
|---|---|---|
| LSD (13 micrograms), Identity of substance known | Experimental | LSD tartrate in tasteless solution (0.13 mL). Subjects will receive LSD, and they (but not the research assistant) will be told the identity of the drug. Receives: Drug: LSD |
| LSD (13 micrograms), Identity uncertain | Active comparator | LSD tartrate in tasteless solution (0.13 mL). Subjects will be told they might receive a stimulant, sedative, low dose of hallucinogen, or placebo, and will receive LSD. Receives: Drug: LSD |
| Placebo, Identity of substance known | Placebo comparator | Distilled water (0.13 mL). Subjects will receive placebo, and they (but not the research assistant) will be told the identity of the drug. Receives: Drug: Placebo |
| Placebo, Identity uncertain | Placebo comparator | Distilled water (0.13 mL). Subjects will be told they might receive a stimulant, sedative, low dose of hallucinogen, or placebo, and will receive placebo. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual Analog Scale (VAS)
Momentary states will be assessed using VAS to measure ratings of 'depressed', 'anxious', 'motivated', and 'energetic', on a scale of 0 (Not at all) to 100 (Very much).
Measured: During in-lab session: Pre-drug, and every 60 minutes post-drug from 0-4 hours
Addiction Research Center Inventory (ARCI)
The ARCI is a 53-item true or false questionnaire that assess effects of specific drug classes. It includes scales measuring: amphetamine (A); benzedrine group (BG; energy and intellectual efficiency); morphine-benzedrine group (MBG; euphoric effects); LSD (hallucinogen-like effects); pentobarbital-chlorpromazine-alcohol group (PCAG; sedative effects); and marijuana (M).
Measured: During in-lab session: Pre-drug, and every 60 minutes post-drug from 0-4 hours
Drug Effects Questionnaire (DEQ)
The DEQ measures overall drug effects. It consists of questions on a visual analog scale about the subjective effects of drugs. Subjects are asked to rate the extent they feel a drug effect, whether they like or dislike the drug effect, and if given a choice would they want to take more of the drug. Scores range from 0-100.
Measured: During in-lab session: Pre-drug, and every 60 minutes post-drug from 0-4 hours
5 Dimensions of Altered States of Consciousness (5D-ASC) scale
The 5D-ASC assesses altered states of consciousness in five domains, and is sensitive to LSD administration (Schmid et al. 2014). Scores range from 0-100.
Measured: End of session (4 hours post-drug)
Ultimatum Game
In this task, participants play the role of responder in a series of single-shot computer interactions. They engage in 60 trials in which they interact with different computer-simulated proposers. On each trial they are allocated $10 to split between themselves and the participant. Participants will receive 60 different monetary offers ranging from fair (50:50 splits) to increasingly unfair (10:90 splits), presented in random order. For each offer, participants must decide whether to accept the offer, in which case both players receive the proposed amounts, or reject the offer, in which case both players receive nothing. This task will measure how the drug affects perception of fairness, and decision-making in social contexts. The task takes approximately a 30 minutes to complete.
Measured: During in lab session: 1.5 hours post-drug
Secondary outcomes (2)
Cardiovascular (Heart rate; beats per minute)
heart rate (HR) will be measured using a portable digital blood pressure monitor.
Measured: During in-lab session: baseline (pre-drug), and every 60 minutes post-drug from 0-4 hours
Cardiovascular (blood pressure; mmHg)
Systolic pressure (SP), and diastolic pressure (DP) will be measured using a portable digital blood pressure monitor.
Measured: During in-lab session: baseline (pre-drug), and every 60 minutes post-drug from 0-4 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jul 2025
- Study start26 Jun 2025
- Primary completion5 Jun 2026
- Study completion5 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (18)Papers the sponsor has linked to this study.
- Other trials for LSDStudies of the same condition, open and under way.
- More trials run by University of ChicagoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Chicago
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- Responsible party
- Sponsor
- Investigators
- Hanna Molla, Principal investigator, University of Chicago
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07061886
- Sponsor's protocol ID
- IRB25-0658
- Other IDs
- 5R01DA002812-35
- Acronym
- MESA-X
- Status last verified
- Jul 2026
- First submitted
- 6 Jun 2025
- Last updated
- 9 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Aron, A., Melinat, E., Aron, E. N., Vallone, R. D., & Bator, R. J. (1997). The Experimental Generation of Interpersonal Closeness: A Procedure and Some Preliminary Findings. Personality and Social Psychology Bulletin, 23(4), 363-377. https://doi.org/10.1177/0146167297234003
Beck, A. T., Steer, R. A., & Brown, G. (1996). Beck Depression Inventory-II (BDI-II). In APA PsycTests
Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers. Biol Psychiatry. 2019 Nov 15;86(10):792-800. doi: 10.1016/j.biopsych.2019.05.019. Epub 2019 Jun 3.
PubMed 31331617de Wit H, Molla HM, Bershad A, Bremmer M, Lee R. Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study. Addict Biol. 2022 Mar;27(2):e13143. doi: 10.1111/adb.13143. Epub 2022 Feb 1.
PubMed 35106880Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 1998 Jul;31 Suppl 2:80-4. doi: 10.1055/s-2007-979351.
PubMed 9754838Fadiman, J and Gruber, J (2025) Microdosing for Health, Healing, and Enhanced Performance, St Martins Group
Fischman MW, Foltin RW. Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict. 1991 Dec;86(12):1563-70. doi: 10.1111/j.1360-0443.1991.tb01749.x.
PubMed 1786488Güth, W, RSchmittberger, B Schwarze (1982) An experimental analysis of ultimatum bargaining. Journal of Economic Behavior & Organization, Volume 3, 367-388
Hammami MM, Al-Gaai EA, Alvi S, Hammami MB. Interaction between drug and placebo effects: a cross-over balanced placebo design trial. Trials. 2010 Nov 19;11:110. doi: 10.1186/1745-6215-11-110.
PubMed 21092089Lyvers MF, Maltzman I. The balanced placebo design: effects of alcohol and beverage instructions cannot be independently assessed. Int J Addict. 1991 Sep;26(9):963-72. doi: 10.3109/10826089109058933.
PubMed 1743824Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):245-58. doi: 10.1002/cpt1971122part1245. No abstract available.
PubMed 5554941McNair, D., Lorr, M., Droppleman, L., (1971). POMS, Profile of Mood States. E. a. I. T. Services.
Metrik J, Kahler CW, Reynolds B, McGeary JE, Monti PM, Haney M, de Wit H, Rohsenow DJ. Balanced placebo design with marijuana: pharmacological and expectancy effects on impulsivity and risk taking. Psychopharmacology (Berl). 2012 Oct;223(4):489-99. doi: 10.1007/s00213-012-2740-y. Epub 2012 May 16.
PubMed 22588253Molla H, Lee R, Tare I, de Wit H. Greater subjective effects of a low dose of LSD in participants with depressed mood. Neuropsychopharmacology. 2024 Apr;49(5):774-781. doi: 10.1038/s41386-023-01772-4. Epub 2023 Dec 2.
PubMed 38042914Murphy RJ, Muthukumaraswamy S, de Wit H. Microdosing Psychedelics: Current Evidence From Controlled Studies. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 May;9(5):500-511. doi: 10.1016/j.bpsc.2024.01.002. Epub 2024 Jan 26.
PubMed 38280630
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Drug Effects on Mood and Behavior - Expectancy
- ClinicalTrials.gov ID
- NCT07061886
- Acronym / sponsor ID
- MESA-X / IRB25-0658
- Conditions
- LSD
- Keywords
- Healthy Adults
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- University of ChicagoUniversity, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- Study start
- 26 Jun 2025 (actual)
- Primary completion
- 5 Jun 2026 (actual)
- Study completion
- 5 Jun 2026 (actual)
- First posted
- 11 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will examine the effects of a single low dose of the 5HT2A agonist LSD (Lysergic Acid Diethylamide) (13 µg) or placebo in individuals who are or are not explicitly told what drug they will receive. Although it is known that expectancies strongly influence subjective responses to most drugs, no studies have examined expectancies on response to a very low dose of LSD. This is especially important in the context of 'microdosing' of drugs. People who practice microdosing typically do so with strong expectations of positive effects, making it difficult to determine whether there is a pharmacological effect. To minimize expectancies in the laboratory, participants are usually not told exactly what drug they will receive (i.e., double-blind), but given a range of possibilities. In the present study, the study team will test half the subjects under single-blind conditions, where the participants (but not the research assistant) will know exactly what they are receiving. Other subjects will receive the usual instructions. Healthy volunteers will receive either a marginally detectable dose of LSD (13 micrograms) or placebo, under conditions where they i) know for sure what drug they are receiving or ii) where the identity of the drug is uncertain. Four groups of subjects (N=12 each) will attend single 4-hour laboratory session. The study team will examine subjective and behavioral responses to the drug in each of four conditions (Known-Drug; Known-Placebo; Uncertain-Drug; Uncertain-Placebo).
Detailed description
Expectancies are known to influence responses to psychoactive drugs. The study team and others have shown previously, using a balanced placebo design, that expectancies influence responses to alcohol, nicotine, caffeine, stimulant drugs, and cannabinoids. In these studies subjects are randomly assigned to one of four conditions: Expect the drug and get the drug; Expect the drug and get placebo; Expect placebo and get the drug; Expect placebo and get placebo. This allows researchers to separate pharmacological effects from expectancy effects.
Recently there has been much discussion about the role of expectancies specifically in responses to psychedelic drugs. Expectancies are especially important in the use of very low doses, referred to as 'microdoses'. These doses are typically at or below the threshold of detectability, but users take them with strong prior beliefs that the drugs improve mood and cognition. The beneficial effects have been difficult to demonstrate under laboratory conditions, perhaps because in the laboratory the drugs are administered without the explicit expectation of benefits, and the administration of the drugs is to some extent blinded. The present study is designed to separate the pharmacological effects of a low dose of LSD from effects that are influenced by expectancies.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| LSD (13 micrograms), Identity of substance known | Experimental | Drug: LSDLSD tartrate in tasteless solution (0.13 mL). Subjects will receive LSD, and they (but not the research assistant) will be told the identity of the drug. |
| LSD (13 micrograms), Identity uncertain | Active comparator | Drug: LSDLSD tartrate in tasteless solution (0.13 mL). Subjects will be told they might receive a stimulant, sedative, low dose of hallucinogen, or placebo, and will receive LSD. |
| Placebo, Identity of substance known | Placebo comparator | Drug: PlaceboDistilled water (0.13 mL). Subjects will receive placebo, and they (but not the research assistant) will be told the identity of the drug. |
| Placebo, Identity uncertain | Placebo comparator | Drug: PlaceboDistilled water (0.13 mL). Subjects will be told they might receive a stimulant, sedative, low dose of hallucinogen, or placebo, and will receive placebo. |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- English Fluency
- High school education or higher
- BMI between 19-30 kg/m2
Key exclusion criteria (10 listed)
- Individuals with a medical condition contraindicating study participation as determined by the study physician (e.g., liver disease, abnormal EKG, liver or cardiovascular disease)
- High blood pressure (>140/90)
- Current suicidal ideation or suicide attempt in past 12 months
- Past year severe substance use disorder
- Personal or first-degree relative with history of psychosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LSDAlso: Lysergic acid diethylamideThe serotonin 2A receptor agonist LSD | Drug | LSD (13 micrograms), Identity of substance known, LSD (13 micrograms), Identity uncertain |
| PlaceboDistilled water (0.26 mL) | Drug | Placebo, Identity of substance known, Placebo, Identity uncertain |
Primary outcome
Visual Analog Scale (VAS)
Time frame: During in-lab session: Pre-drug, and every 60 minutes post-drug from 0-4 hours
Momentary states will be assessed using VAS to measure ratings of 'depressed', 'anxious', 'motivated', and 'energetic', on a scale of 0 (Not at all) to 100 (Very much).
Addiction Research Center Inventory (ARCI)
Time frame: During in-lab session: Pre-drug, and every 60 minutes post-drug from 0-4 hours
The ARCI is a 53-item true or false questionnaire that assess effects of specific drug classes. It includes scales measuring: amphetamine (A); benzedrine group (BG; energy and intellectual efficiency); morphine-benzedrine group (MBG; euphoric effects); LSD (hallucinogen-like effects); pentobarbital-chlorpromazine-alcohol group (PCAG; sedative effects); and marijuana (M).
Drug Effects Questionnaire (DEQ)
Time frame: During in-lab session: Pre-drug, and every 60 minutes post-drug from 0-4 hours
The DEQ measures overall drug effects. It consists of questions on a visual analog scale about the subjective effects of drugs. Subjects are asked to rate the extent they feel a drug effect, whether they like or dislike the drug effect, and if given a choice would they want to take more of the drug. Scores range from 0-100.
5 Dimensions of Altered States of Consciousness (5D-ASC) scale
Time frame: End of session (4 hours post-drug)
The 5D-ASC assesses altered states of consciousness in five domains, and is sensitive to LSD administration (Schmid et al. 2014). Scores range from 0-100.
Ultimatum Game
Time frame: During in lab session: 1.5 hours post-drug
In this task, participants play the role of responder in a series of single-shot computer interactions. They engage in 60 trials in which they interact with different computer-simulated proposers. On each trial they are allocated $10 to split between themselves and the participant. Participants will receive 60 different monetary offers ranging from fair (50:50 splits) to increasingly unfair (10:90 splits), presented in random order. For each offer, participants must decide whether to accept the offer, in which case both players receive the proposed amounts, or reject the offer, in which case both players receive nothing. This task will measure how the drug affects perception of fairness, and decision-making in social contexts. The task takes approximately a 30 minutes to complete.
2 secondary outcomes
Cardiovascular (Heart rate; beats per minute)
Time frame: During in-lab session: baseline (pre-drug), and every 60 minutes post-drug from 0-4 hours
Cardiovascular (blood pressure; mmHg)
Time frame: During in-lab session: baseline (pre-drug), and every 60 minutes post-drug from 0-4 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2026.
- BackgroundAron, A., Melinat, E., Aron, E. N., Vallone, R. D., & Bator, R. J. (1997). The Experimental Generation of Interpersonal Closeness: A Procedure and Some Preliminary Findings. Personality and Social Psychology Bulletin, 23(4), 363-377. https://doi.org/10.1177/0146167297234003
- BackgroundBeck, A. T., Steer, R. A., & Brown, G. (1996). Beck Depression Inventory-II (BDI-II). In APA PsycTests
- Background: PubMed 31331617Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers. Biol Psychiatry. 2019 Nov 15;86(10):792-800. doi: 10.1016/j.biopsych.2019.05.019. Epub 2019 Jun 3.
- Background: PubMed 35106880de Wit H, Molla HM, Bershad A, Bremmer M, Lee R. Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study. Addict Biol. 2022 Mar;27(2):e13143. doi: 10.1111/adb.13143. Epub 2022 Feb 1.
- Background: PubMed 9754838Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 1998 Jul;31 Suppl 2:80-4. doi: 10.1055/s-2007-979351.
- BackgroundFadiman, J and Gruber, J (2025) Microdosing for Health, Healing, and Enhanced Performance, St Martins Group
- Background: PubMed 1786488Fischman MW, Foltin RW. Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict. 1991 Dec;86(12):1563-70. doi: 10.1111/j.1360-0443.1991.tb01749.x.
- BackgroundGüth, W, RSchmittberger, B Schwarze (1982) An experimental analysis of ultimatum bargaining. Journal of Economic Behavior & Organization, Volume 3, 367-388
- Background: PubMed 21092089Hammami MM, Al-Gaai EA, Alvi S, Hammami MB. Interaction between drug and placebo effects: a cross-over balanced placebo design trial. Trials. 2010 Nov 19;11:110. doi: 10.1186/1745-6215-11-110.
- Background: PubMed 1743824Lyvers MF, Maltzman I. The balanced placebo design: effects of alcohol and beverage instructions cannot be independently assessed. Int J Addict. 1991 Sep;26(9):963-72. doi: 10.3109/10826089109058933.
- Background: PubMed 5554941Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):245-58. doi: 10.1002/cpt1971122part1245. No abstract available.
- BackgroundMcNair, D., Lorr, M., Droppleman, L., (1971). POMS, Profile of Mood States. E. a. I. T. Services.
- Bershad et al., 2019Link provided by the sponsor.
- Dittrich, 1998Link provided by the sponsor.
- Hammami et al., 2010Link provided by the sponsor.
- Metrik et al., 2012Link provided by the sponsor.
- Molla et al., 2024Link provided by the sponsor.
- Murphy et al., 2024Link provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for LSD
Not yet recruitingPhase 1
Shortened LSD Intervention for Major Depressive Disorder
Major Depression Moderate, Major Depression Severe
Active, not recruitingPhase 2
Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache
Cluster Headache
RecruitingPhase 2
LSD Treatment for Persons With Alcohol Use Disorder
Alcohol Use Disorder (AUD)
Not yet recruitingPhase 2
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol)
Lysosomal Storage Disorders, Sandhoff Disease
RecruitingPhase 1
Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA
SLE (Systemic Lupus), RA - Rheumatoid Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hanna Molla principal investigator
University of Chicago
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing LSD in people with LSD, run by University of Chicago at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual Analog Scale (VAS) (time frame: During in-lab session: Pre-drug, and every 60 minutes post-drug from 0-4 hours). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07061886, which also lists 18 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2026.